KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Operating Expenses (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Operating Expenses for 17 consecutive years, with $11.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 9.33% to $11.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $38.9 billion, a 31.43% decrease, with the full-year FY2025 number at $38.9 billion, down 31.43% from a year prior.
  • Operating Expenses was $11.0 billion for Q4 2025 at Bristol Myers Squibb, up from $9.1 billion in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $23.4 billion in Q1 2024 to a low of $8.2 billion in Q1 2025.
  • A 5-year average of $10.4 billion and a median of $9.9 billion in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 172.92% in 2024, then plummeted 64.8% in 2025.
  • Bristol Myers Squibb's Operating Expenses stood at $10.1 billion in 2021, then dropped by 5.73% to $9.5 billion in 2022, then rose by 2.68% to $9.8 billion in 2023, then increased by 24.12% to $12.2 billion in 2024, then fell by 9.33% to $11.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Operating Expenses are $11.0 billion (Q4 2025), $9.1 billion (Q3 2025), and $10.5 billion (Q2 2025).